Sanofi will invest more than €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France as part of a €3.5 billion programme in the cou
BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside